STAT+: At BIO, a glimpse behind Lilly and Chai’s partnership

Article excerpt

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Several of my colleagues are at the BIO conference in San Diego this week (and two of them have dispatches below). Say hi if you see them! The need-to-know this morning Regenxbio said it will apply for accelerated approval for its gene therapy for Duchenne muscular dystrophy, amid industry hopes the FDA is showing renewed openness to rare disease treatments. Ophthalmology startup catches investors’ attention Ollin Biosciences has raised $330 company in a Series B round, one of the largest such rounds for a biotech company in the last two years. Continue to STAT+ to read the full story…